CD4 and autoimmune disease: Therefore, Bhlhe40 could be a pivotal transcriptional regulator for both antigen-specific and bystander MP CD4+ T cells in the context of CNS inflammation and targeting Bhlhe40 in CD4+ T cells may serve as a novel treatment strategy to control autoimmune diseases.